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CHAPTER I                                                                                                    
INTRODUCTION 
1.1 Background 
Osteoporosis is a chronic silent disease and is considered a major public health 
threat in the United States [25]. Currently, about ten million individuals suffer from this 
debilitating disease and approximately 34 million people have low bone mass, which 
increases their risk of osteoporosis [58]. Although in this country there are a number of 
anti-osteoporotic drugs available, unfortunately these drugs are associated with certain 
risks and side effects. Additionally, compliance is low and women, in particular, are 
interested in using alternative/adjunctive therapies including functional foods and their 
bioactive components.  
Our recent findings suggest that dried plum is highly effective in positively 
modulating bone mass in rat models of osteoporosis [40] as well as improving bone 
biomarkers over a three-month period in postmenopausal women [19].  
More recently, in a preliminary study, dried plum dose-dependently increased 
steady-state mRNA levels of bone matrix proteins demonstrating the effects of dried 
plum at the molecular level. The objectives of the present study were to: (1) elucidate the 
mechanisms by which dried plum polyphenol extract increases bone formation and (2) 
determine whether dried plum polyphenol extract poses some anti-inflammatory 
properties. To achieve the first objective, we utilized osteoblast-like cells (MC3T3-E1 cell-
line sub-clone 4 from mouse culveri). For examining the anti-inflammatory properties of 





1.2 Research Objectives 
1.2.1 Objective 1  
In order to find the most effective dose of polyphenol extract in bone 
mineralization and bone formation, MC3T3-E1 cells were treated with different doses 0, 
0.5, 1, 10, 100, and 1000 µg/ml of plum extract.  Cells were treated for 15 days and 
thereafter, alkaline phosphatase, a marker of bone formation, were measured in cell 
supernatants. Bone mineralization were assessed at fifteen days by staining the cells with 
alizarin red. Griess assay were performed every three days during a fifteen-day period on 
the supernatants treated with different concentrations of polyphenol extract. We also 
attempted measuring nitric oxide and cyclooxigenase (COX-2) in these cells to assess the 
anti-inflammatory property of polyphenol extract. However, since the number of MC3T3-
E1 cells were limited, we predicted that we may not be able to assess these parameters in 
theses cells. Hence, the same parameters were assed using macrophages as discussed 
under objective 2. (see Figure 1) 
1.2.2 Objective 2  
 For this objective, RAW 264.7 macrophages were stimulated with LPS. Cell 
viability were measured using  5 different concentrations of polyphenol extract (0, 1, 10, 
100, or 1000 µg/ml) in the presence (1µg/ml) or absence of LPS, known to induce 
inflammation, at 24 and 48 hours. Furthermore, the dose-dependent effects of dried plum 










We hypothesized that polyphenols, the active components in dried plums, 
enhancing bone formation and reducing the production of pro-inflammatory molecules. 
To test this hypothesis we proposed two specific aims as follows: 
1.3.1 Aim 1  
To examine the dose-dependent effects of dried plum polyphenols extract in 
increasing bone formation and mineralization by using osteoblast-like cells (MC3T3-E1).  
1.3.2 Aim 2  
To evaluate the dose-dependent effects of dried plum polyphenols on pro-
inflammatory molecules such as nitric oxide and cyclooxygenase-2 using macrophage 
cells. 
 
Figure 1. Schematic mechanism of actions of inflammatory factors on osteoporosis and 
stimulation/inhibition mechanism by which dried plum polyphenols may influence these 
pathways. 
 























CHAPTER II                                                                                                    
REVIEW OF THE LITERATURE 
 
2.1 Osteoporosis 
By the end of next decade, approximately one in four Americans will be 65 years of 
age or older and the number of people aged 85 years will double during this period [43], 
[123]. Trends in population aging have been accompanied nationally by an increased 
concern for the health-related needs of older people. Age-related bone loss that results in 
osteoporosis is a significant health problem in the elderly population [60]. The prevalence of 
age-related bone loss is greater in women than in men [95],[124] and in 25 to 30% of aging 
women the loss results in major orthopedic problems [22]. In the United States alone, a 
conservative estimate is that 30 million people have osteoporosis that results in more than 
1.2 million fractures per year in people 45 years and older [1]. About 50,000 deaths result 
from hip fractures annually and the cost to society of osteoporosis and related problems has 
been estimated at over $18 billion dollars per year [46]. Therefore, osteoporosis is an 
enormous public health problem with immense socioeconomic significance.  
 Although osteoporosis is common in elderly women, men also have an increased 
risk of osteoporosis with aging [71]. Whereas osteoporosis has been studied mostly in 
women, there is paucity of such studies in men. Age-related bone loss in men has been 
recognized for many years but its pathogenesis has not been understood. Over the years 
several hypotheses of the etiology of osteoporosis due to androgen deficiency have been 





alterations in the levels or activities of the calcium regulating hormones, but with differing 
emphasis on the relative contribution of parathyroid hormone (PTH), calcitonin, and 1,25 
dihydroxyvitamin D (1,25(OH)2vitamin D) [117], [84]. Currently, none of the hypotheses 
has been adopted exclusively of the others and the mechanisms by which androgens exert 
their effects on bone and calcium homeostasis remain unclear. Osteoporosis due to aging 
may be associated with intestinal malabsorption of calcium [82], [101], the major building 
block of bone. Although impaired calcium absorption both in males and females is believed 
to aggravate negative calcium balance and contribute importantly to bone loss in 
osteoporotic patients [63], other dietary and lifestyle factors aside from calcium, vitamin D 
and weight-bearing exercise remain unexplored. However, there are a number of other 
factors that may have profound health benefits on bone including functional foods and their 
bioactive components which, in part, is the focus of this project. Pant bioactive components 
have been referred to as phytochemicals. Phytoestrogens, are phytochemicals that are 
structurally similar to estrogen and may act as either as weak estrogen agonists or antagonist 
depending on the tissue and the estrogen level [34].    
2.1.1 Molecular and cellular mechanism of estrogen on bone 
Before the findings of Women’s Health Initiative study become publicized [48], 
estrogen was the most important sex steroid for maintaining bone, as suggested by the 
beneficial use of estrogen replacement therapy used to treat postmenopausal bone loss 
[48].  Estrogen acts through both estrogen receptor alpha (ERα) and beta (ERβ).  
Estrogen receptor α and β share a conserved deoxyribose nucleic acid (DNA) binding 





domain that contains a transactivation activity (AF-1) that is responsible for interacting 
with proteins of the core transcriptional machinery [104].  These receptors are nuclear 
receptors so they are located on the osteoblast and osteoclast nuclear membrane.  
Estrogen moves into the cell via diffusion and binds to the AF-2 site located in the 
ligand-binding domain [90], [73].  Estrogen is 245 angstroms, which allows for a perfect 
fit within the cavity for binding [118].  Hormone recognition is by hydrogen bonds and 
the non-polar properties of estrogen [105] The steroid is enveloped in a hydrophobic 
pocket, 450 angstroms, which is sealed by the helix 12 [30].  This closure is essential for 
the recruitment of co-activators to the AF-2 site and subsequent initiation of the ribose 
nucleic acid (RNA) polymerase and transcription [30].  The two receptors can bind to the 
estrogen response elements (ERE) in DNA which they may act as either homodimer or 
heterodimer α /β to initiate transcription [30]. Or they can bind to the AP-1 site on the 
DNA via the proteins Fos and Jun [28].  Since ERα and ERβ adopt distinct 
conformations upon binding, it is hypothesized that this will determine the repertoire of 
protein cofactors interacting with each ligand-activated, DNA-bound receptor which then 
participates in the transcription initiated complex [30].  
Extensive evidence suggests that estrogen directly modulate osteoblast activity, 
indirectly regulate osteoclast activity, and regulate a coupling talk between osteoblasts 
and osteoclasts [78]. However, it remains controversial whether estrogen directly 
stimulates bone formation or its effects occur secondary to a tight coupling of formation 
and resorption.  The most consistent results demonstrate that estrogen increases the type I 
collagen formation and the production of transforming growth factor-β (TGF-β), and 





Inconsistent research results may reflect low, variable levels in cells secondary to culture 
and isolation method plus estrogen demonstrates atypical responses based on the varying 
artificial ER levels [142].  Overall, osteoclasts have less investigational studies secondary 
to limited number in bone and difficulty obtaining cells [114].  The most accepted 
mechanism of estrogen action on bone is the regulation of bone resorptive cytokine 
synthesis by osteogenic and monocyte/macrophage lineage [114].   However, controversy 
exist over which is the dominate cytokine regulated by estrogen and which is responsible 
for the increase in bone resorption in estrogen-deficient conditions [114].   There are 
potential mechanisms that try to explain the regulation of osteoclasts: estrogen inhibits 
osteoblastic synthesis of IL-6 which regulates osteoclastic activity and osteoblastic 
activity [114] and estrogen stimulates monocytes and macrophage synthesis of IL-1 and 
TNF-α which cause increased resorption.  Supportive evidence comes from an 
investigation that demonstrates that a blockade of IL-1 and TNF-α completely prevents 
ovariectomized-induced bone loss in rats [114]. These mechanisms are not mutually 
exclusive, yet all three cytokines may be involved in culminating increased resorption 
[114]. Overall, estrogens action on bone may control proliferation and differentiation of 
preosteobasts and osteoclasts; activity of mature osteoblasts and osteoclasts; “coupling” 
between mature osteobasts and osteoclasts; “coupling” between preosteoblasts and 
preosteoclasts; production of bone-resorbing cytokines by osteoblasts; osteoclasts, 






2.1.2 Expression of estrogen receptors in bone  
Estrogen receptor α and β are localized in the epiphysis growth plate 
chondrocytes in humans and rodents; however, the relative abundance is not known [76]. 
It has been reported the ER-α predominates in trabecular osteoblasts versus cortical 
osteoblasts; however, lines the osteoclasts and osteocytes with lower levels [138].  The 
cellular distribution of ER-β is unknown; however, higher levels have been reported in 
trabecular bone versus cortical bone [137].  In comparison of the two ERs, ERα was the 
predominant form expressed in the osteoblast precursors (bone marrow stromal cells) and 
in the trabecular bone [122].  What factors regulate the expression of ERα and β and the 
changes that occur in different pathological conditions is unknown [141].    
2.2 FDA-approved Medications for the Pharmacological Treatment of Osteoporosis 
Current approved drugs by the US Food and Drug Administration (FDA) include 
bisphosphonates (alendronate, ibandronate and risedronate), calcitonin, estrogens, 
parathyroid hormone and raloxifene which are approved for the prevention and/or 
treatment of osteoporosis (NOF,2006). 
2.2.1. Hormone replacement therapy 
Since the use of estrogen replacement therapy or hormone replacement therapy 
(HRT) is no longer clinically relevant in US or other countries, this subject will not be 
discussed in details. For instance, Thunell and colleagues (BJOG, 113(1):15-20, 2006) 
studied the changes in attitudes, knowledge and management strategies concerning 
hormone replacement therapy (HRT) among 1,323 practicing gynaecologists in Sweden 





concerning HRT. They were asked to complete this questionnaire at two different time 
points (1996 and 2003). They were also asked about their own use of HRT. The response 
rate was 76% in 2003 when 11% of the gynecologists thought that all women without 
contraindications should be offered HRT compared with 44% in 1996 and 89% found it 
difficult to evaluate pros and cons with HRT in a clinical situation (74% in 1996). A great 
number of gynecologists in 2003 also believed that HRT increased the risk for breast 
cancer (95% vs 71%). Twenty-five percent of gynecologists in 2003 indicated that risk 
factors for osteoporosis were the sole indications using HRT (60% in 1996). Current 
ischaemic heart disease was considered to be an indication for HRT by 7% in 2003 (60% 
in 1996). In 2003, the use of HRT was reported by 71% of postmenopausal 
gynaecologists (88% in 1996). In summary, the dindings of this study indicate that 
Swedish gynaecologists similar those in US are more cautious in their management 
strategies concerning prescribing HRT in 2003 compared to1996. This change in attitude 
of both gynecologists and patients is largely influence by the findings of Heart and 
Estrogen/Progestin Replacement Study [59] and Women's Health Initiative [64] studies.  
2.2.2. Bisphosphonates   
Bisphosphonates are structural analogues of pyrophosphate. Their metabolic 
actions inhibition of hydroxyapatite formation, inhibition of bone resorption and 
alteration of serum phosphorus levels [67].  There are several bisphosphonates; however, 
the major drugs for osteoporosis are alendronate, etidronate, and risedronate.  
Bisphosphonates interfere with osteoclast action [119] and have demonstrated a number 





resorbing osteoclasts [120]; inhibit protein tyrosine phosphatases [107] and induce 
apoptosis [106]. 
Etidronate was the first bisphosphonate to be tested in osteoporosis [57]. Later a 
large randomized controlled trial was published with the bisphosphonate, Alendronate 
[115].  Alendronate, trade name Fosamax, by Merck Phamaceuticals, was FDA approved 
in 1996 for the prevention and treatment of osteoporosis.  Daily treatments of alendronate 
have shown to reduce bone loss and increase bone density in the spine and hip of 
postmenopausal osteoporotic women [65].  The osteoclasts increased bone resorption rate 
was inhibited and allowed for the usual bone turnover rate to resume without suppressing 
bone mineralization.  Side effects include nausea, constipation, diarrhea, and abdominal 
pain. The third bisphosphonate used for the treatment and prevention of osteoporosis is 
actonel, risedronate, which was approved by the FDA in April 2000. This is classified as 
a bone-resorptive inhibitor.  
 2.2.3 Raloxifene  
Raloxifene is included in a group of compounds that are collectively considered 
selective estrogen receptor modulators (SERMs). SERMs are nonsteroidal compounds 
that possess agonist and antagonist properties of estrogen action on the ER [94], [93]. The 
agonist or antagonist activity of a particular SERM may be related to the class of ER 
present in the cell or how the conformation of the ligand-ER complex is recognized [80].  
Raloxifene is a benzothiophene derivative that was approved by the Food and 
Drug Administration (FDA) in December 1997 for the treatment of osteoporosis.  





effects on the skeleton and cardiovascular system, but antiestrogen effects on the breast 
and endometrium [2].  
A limited number of studies with postmenopausal women showed that a 60 mg 
dose of raloxifene significantly reduced markers of bone metabolism, alkaline 
phosphatase osteocalcin and urinary type I collagen C-telopeptide [131], [98].  Beneficial 
results were also reported with increased bone mass in lumbar spine, total hip, and total 
body with treatment of raloxifene in postmenopausal women [97].  Not only has 
raloxifene demonstrated beneficial results with bone metabolism and bone mass but also 
serum lipoproteins.   
Raloxifene has an estrogenic agonist effect on the serum lipoproteins.  In a study 
of postmenopausal women, raloxifene lowered low-density lipoprotein (LDL) to a similar 
extent as HRT; however, it did not show an increase in HDL as that observed with HRT 
[132].  This study also showed some beneficial effects of raloxifene over HRT: 
triglycerides (TG) levels did not increase with raloxifene whereas HRT increased TG and 
raloxifene lowered serum fibrinogen compared with no effect from HRT.  
Breast cancer and uterine cancer where also monitored during particular studies of 
raloxifene and its efficacy in osteoporosis.  One of the larger studies Multiple Outcomes 
of Raloxifene Evaluation (MORE) included 7,704 postmenopausal women with a 
meanage of 65 years reported a 74% reduction in risk of breast cancer [35].  Studies of 
postmenopausal women have not shown to affect the endometrial thickness [38]; 
however, other evidence has reported an increase in uterine weight and uterine epithelial 





Overall, the changes observed with SERMs are often less marked than those 
observed with HRT. The risk-benefit of the emerging SERMs needs to be better defined 
and evaluated.    
2.2.4 Calcitonin   
Calcitonin is a polypeptide hormone made in the C cells in the thyroid [113]. It 
acts on the osteoclast by inhibiting the proliferation of progenitors as well as the 
differentiation of committed precursors [134].  Calcitonin is classified as an 
antiresorptive agent, which was approved by the FDA in 1995 for the treatment of 
osteoporosis. 
2.2.5. Teriparatide 
Teriparatide is a trade name for parathyroid hormone (PTH) which is a major 
calcium-regulating hormone in humans [42]. PTH maintains serum calcium by 
stimulating bone resorption, regulating renal calcium excretion, and indirectly affecting 
intestinal calcium absorption[85]. Recent FDA approval of teriparatide, i.e. recombinant 
PTH, has led to the availability of the first anabolic agent that significantly stimulates 
new bone formation and reverses bone loss [116]. While the potential for PTH therapy has 
been received with much enthusiasm, it is not without risk and for many patients may be 
cost prohibitive [24] teriparatide therapy should be reserved as a last option because of 





2.3. Other Agents Aside from Calcium and Vitamin D that May Have Bone 
Protective Effects 
2.3.1 Phytoestrogens 
Phytochemicals are plant-derived compounds.  Among the phytochemicals are 
phytoestrogens, which is a broad group of nonsteroidal compounds of diverse structure 
that have been shown to bind to the ER in animals and humans [32].  The major types of 
phytoestrogens are the lignans and isoflavones [77].  There are three main classes of 
phytoestrogens: Isoflavones such as genistein and daidzein, both of which are found in 
soy; lignans such as enterodiol and enterolactone, both of which are found in flaxseed; 
cCoumestans which is found in bean sprouts and alfalfa. Isoflavones are compounds that 
are structurally and functionally similar to estradiol [125] based on their displayed 
binding and stimulating effects on the estrogen receptor [126].  Isoflavones are thought to 
exert both estrogenic and antiestrogenic effects, depending on the tissue in which they act 
[4]. Using human cell culture bioassays, isoflavone and estradiol demonstrated equivalent 
levels of bioactivity with the ERβ [79]. A phenolic structure seems to be a prerequisite 
for binding to ERs which isoflavones contain [47]. More specifically the isoflavone 
genistein seems to have more binding affinity for ER-β than ER-α [81].  
The proposed similarities between estrogen and isoflavone, biochemical structure 
and function, fueled the speculation and investigations regarding the potential benefits of 
soy and isoflavone. The ovariectomized rat model is a common animal model that has 
indicated that soy protein may have a promising protective effect on the ovariectomized 
rat bone.  In 1998, it was initially reported that genistein displayed a bisphasic effect on 





calcium diet Anderson et al. 1998 [5].  After two weeks of treatment for the young rats 
and five weeks of treatment for the lactating rats, genistein at the lowest dose of 1.0 mg/d 
helped prevent ovariectomy-induced, bone changes to an extent similar to the effects of 
conjugated equine estrogens (5µg/d).  In 1996, another study by Arjmandi et al. [9] study 
supported the therapeutic potential of soy protein on rat bone. This study investigated the 
effects of soy protein in the same ovariectomized rat model.  The femoral bone density of 
the soy treated group was significantly lower than the estrogen administered and sham 
groups; however, significantly higher than the ovariectomized casein fed group.  The 
bone density of the fourth lumbar vertebra of the soy group and the estrogen group were 
equal and significantly higher than the casein and sham group.  The results suggested a 
more protective benefit on the trabecular bone than the cortical bone. In 1998, a follow-
up study evaluated whether isoflavones in soy protein are responsible for the bone-
protective effects [11], Arjmandi et al., 1998 [12].  The treatment groups included a low 
isoflavone containing soy protein-based diet and normal isoflavone containing diet. The 
loss of bone mineral density was prevented by the soy diet with normal isoflavone 
content but not by the low isoflavone content soy diet.  These results suggest that the 
bone protective substrate in the soy is correlated to the isoflavone content.  Two other 
studies suggested that genistein may be the bone bioactive isoflavone.  Ovariectomized 
rats were fed a diet containing 30 µmol genistein/d for four weeks [27]. The dry femoral 
mass was 12% higher in the genistein fed group compared to the controls.  Another study 
treated ovariectomized rats with 5 and 25 µg genistein/g body wt injected 
subcutaneously. Genistein significantly reduced ovariectomized tibia bone mineral loss; 





 The potential role isoflavones demonstrate on bone in rats lead to investigations 
that examined its effect on the human bone.  In 1998, a study by Potter et al., reported 
that after 6 months of treatment, the lumbar spine bone mineral density increased 
significantly in postmenopausal women who consumed 40 g/day soy protein containing 
2.25 mg isoflavones/g protein daily compared with baseline values.  However, bone 
density remained the same in the women who consumed the same amount of soy protein 
but with only 1.39 mg isoflavones/g protein [112] .  A recent human investigation of 
primenopausal women reported that soy isoflavones attenuated bone loss in the lumbar 
spine [3].  This 24 week study investigated the effects of isoflavone-rich soy protein (80.4 
mg aglycone components/d), isoflavone-poor soy protein (4.4mg aglycone 
components/d) and whey protein.  The aglycone components are the unconjugated parent 
forms of the isoflavones. 
The exact mechanism of isoflavone on bone is unknown; however, there have 
been some proposed mechanisms.  One investigation reported that genistein significantly 
inhibited dibutyryl cyclic adenosine monophosphate induced osteoclast-like cell 
formation in the mouse marrow culture [55].  The inhibitory action of genistein may 
involve the cyclic AMP signaling [54].   Another investigation demonstrated that 
genistein directly suppresses osteoclasts in vitro [53]. From this investigation, it was 
suggested that isoflavone may induce apoptosis which is mediated through the 
intracellular calcium signaling [52].  Not only has isoflavone shown a positive effect on 
suppressing bone loss, yet it has also demonstrated anabolic potential.  Genistein and 
daidzein both indicated an anabolic effect on bone metabolism in rat tissue culture in 





2.3.2 Flaxseed and bone 
  Among edible plant foods, flaxseed is by far the richest source of lignans, which 
are reported to have both weak estrogenic and anti-estrogenic activities [36]. Lignans are 
structurally similar to tamoxifen, which has beneficial effects on bone [139]. Flaxseed is 
also a rich source of polyunsaturated fatty acid (PUFA), especially alpha-linolenic acid 
(18:3 n-3) [70]. Alpha-linolenic acid may decrease the rate of bone resorption by 
inhibiting the biosynthesis of prostaglandins [135]. Lignans present in flaxseed may also 
possess antioxidant properties. Oxygen-derived free radicals, which are formed by a 
number of phagocytes including monocytes, macrophages, and neutrophils, have been 
reported to increase in chronic inflammatory diseases, aging, and osteoporosis. In vivo 
and in vitro findings indicate that free radicals generated in the bone environment 
enhance osteoclast formation and bone resorption. Hence, flaxseed may reduce the rapid 
rate of bone loss experienced by postmenopausal women, in part, by enhancing 
antioxidant status. We have previously reported [6] that flaxseed can potentially exert 
positive effects on bone of postmenopausal women. In a follow-up study, we assigned 60 
postmenopausal women not on HRT to receive either 40 g flaxseed or a 40 g wheat-based 
comparative control supplement for three months. Our results indicates no amelioration 
of serum and urinary biomarkers of bone metabolism with flaxseed. Whether a longer-
term study using bioactive components of flaxseed such as lignans or its oil can exert a 
positive influence on BMD and BMC remains to be explored. 
2.4 Evidence for Beneficial Effects of Dried Plums on Bone 
Animal studies and a 3-month clinical trial conducted by Arjmandi and 





bone biomarkers. The animal data showed that dried plum (Prunus domestica L.)  
reverses bone loss in two separate animal models. Finding by Deyhim et al. [39];[20] 
showed that dried plum prevented the ovariectomy-induced reduction in BMD of the 
femur and lumbar vertebra. Serum IGF-1, which is associated with enhanced bone 
formation, was also increased by the dried plum treatment. In follow up study [40], rats 
were ovariectomized and allowed to lose bone before the initiation of treatment. Dried 
plum as low as 5% (w/w), restored BMD to the level of intact rats.  More importantly, 
dried plums reversed the loss of trabecular architectural properties such as trabecular 
number and connectivity density, and trabecular separation. This observation is unique to 
dried plums in comparison with soy or its isoflavones[17], [10], flaxseed [7];[88] and 
apples[16]. According to Lane et al. [83] once trabecular bone is lost, it would be difficult 
to restore it. 
 Our other findings [45];[129] have also shown the effectiveness of dried plum in 
reversal of bone loss due to skeletal unloading. In these studies, rats were either hind limb 
unloaded (HLU) or remained ambulatory (AMB) for twenty-one days to induce 
osteopenia. After confirming bone loss duo to HLU, rats were treated with dried plum or 
injected with PTH. Analysis of BMD and trabecular bone structure by micro-computed 
tomography (µCT) revealed that dried plum enhanced bone recovery during re-
ambulation following skeletal unloading and had comparable effects to PTH[44]; [128]. 
In addition to bone density, architectural arrangement is also known to affect bone 
strength according to McCreadie and Goldstein et al. 2000 [92], [62].These animal 
findings along with significant increases in serum alkaline phosphatase (ALP) and IGF-1 





 In addition to the animal studies, a 3-month clinical trial by Arjmandi and 
colleagues [8] indicated that the consumption of 100 g dried plum daily by 
postmenopausal women significantly increased serum markers of bone formation, total 
ALP, bone-specific ALP ( BSAP), and IGF-1 by 12, 6, and 17%, respectively. The 
increase in BSAP observed in that study is important because some studies have shown 
that clinically relevant doses of bone forming agents such as sodium fluoride, growth 
hormone and PTH take several months to moderately increase serum levels of BSAP 
[66]. In addition to the increase in BSAP observed in a short-term study by Arjmandi et 
al. 2002 [15], same study also reported that IGF-1 was elevated in women consuming 
dried plum. The observations of a 6% increase in BSAP and a 17% increase in serum 
IGF-1 after three months of consumption of dried plum further support our hypothesis 
that dried plum will significantly improve bone mineralization as proposed in the present 
study. From antiresorptive point of view, animal findings reported earlier [130], [20] has 
observed dried plum’s antiresorptive properties in rats as assessed by urinary excretion of 
tritium-labeled tetracycline. Additionally, the findings of three month clinical study by 
Arjmandi et al. 2002 [14] showed that urinary helical peptide, a marker of bone 
resorption, was reduced by 10% although not significantly in the group that received 
dried plum.  
 Although the exact osteoprotective component(s) of dried plum is unknown, dried 
plums are rich in phenolic compounds such as neochlorogenic acid and chlorogenic acid, 
which act as antioxidants[75], [100]. Antioxidants that scavenge potentially damaging 
free radicals have been shown to inhibit bone resorption and stimulate bone formation 





(ORAC) ranking among the most commonly consumed fruits and vegetables [91]. More 
recently, Kayano et al.[74], have isolated several ortho diphenolic and mono hydroxyl 
phenolic compounds with ORAC values as high as 4.68 mol from dried plum. Therefore, 
the beneficial effects of dried plum on bone may be mediated partially through its 
antioxidant properties. 
 Dried plum also contains significant amounts of boron than most fruits. Boron has 
been shown to modulate bone and calcium metabolism [103], and play an important role 
in preserving BMD [102]. A study by Chapin et al. 1997 [31] also showed that rats that 
were fed diets containing 20-200 mg boron/100g diet had significantly improved 
vertebral strength. Nonetheless, the boron levels used in that animal study far exceed the 
upper limit for humans, which is 20 mg of boron per day. One-hundred grams of dried 
plum deliver about 2 to 3 mg boron which will not add a substantial amount of boron to 
one’s daily intake. Although these limited studies bring forth evidence that boron may be 
involved in protecting skeletal health, it is doubtful that the boron alone at the levels 
present in dried plum would substantially affect bone. 
 Dried plum is also a good source of other nutrients such as potassium and vitamin 
K [133], all of which have been reported to influence bone. Tucker and colleagues 
investigated both cross sectional and longitudinal relationships between potassium and 
BMD using a Framingham Heart Study database and concluded that potassium 
contributes to the maintenance of BMD in men and women. Additionally, higher intakes 
of potassium have been shown to reduce bone resorption, particularly in the face of high 





In terms of vitamins, dried plum contains high amounts of vitamin K (i.e. 59.5 µg 
phylloquinone/100 g) among commonly consumed foods [41]. Vitamin K influences 
bone health by improving calcium balance [68] and is a co-factor needed for γ-
carboxylation of osteocalcin. γ-Carboxylated osteocalcin promotes normal bone 
mineralization by regulating the growth of hydroxyapatite crystals[69]. A study by Braam 
et al. 2003 [29] showed that Vitamin K supplementation at the level of 1000 µg daily for 
a period of three years retarded loss of lumbar spine BMD. This level is nearly 17 times 
higher than that present in 100 g dried plum.  
 The above discussion emphasizes that the bone protective effects of dried plum 
cannot be merely attributed to any one of its components and this is the reason that at this 
initial stages of this cell culture study used died plum extract rather than purified 
compounds from dried plum. It is imperative to initially evaluate the beneficial effects of 
whole extract rather than its isolated components. In support of this statement, Messina et 
al. 2001 [96] has indicated that “using a single chemical, such as an individual 
polyphenolic compound or a combination of a few, may hinder, rather than facilitate our 





CHAPTER III                                                                                                    
RESEARCH DESIGN AND METHODS 
In this study we used two different types of cell lines, osteoblast-like cells 
(MC3T3-E1 cells) and raw macrophages. MC3T3-E1 cells originated from mouse calvarias 
(ATCC, VA, USA) and macrophage cells came from mouse bone marrow RAW-264 
(ATCC, VA, USA). 
3.1 Experimental Design 
3.1.1 Objective 1
 
To examine the dose-dependent effects of dried plum polyphenols extract in 
increasing bone formation and mineralization using osteoblast-like cells (MC3T3-E1) 
Experimental design to satisfy the first objective is given in Table 1. 
 






1 Complete α-MEM media 0 µg/ml 
2 Complete α-MEM media with dried plum extract 0.5 µg/ml 
3 Complete α-MEM media with dried plum extract 1 µg/ml 
4 Complete α-MEM media with dried plum extract 10 µg/ml 
5 Complete α-MEM media with dried plum extract 100 µg/ml 
6 Complete α-MEM media with dried plum extract 1000 µg/ml 










3.1.2 Objective 2 
To evaluate the dose-dependent effects of dried plum polyphenols extract on pro-
inflammatory molecules such as nitric oxide and cyclooxygenase-2 using macrophade 
cells Experimental design to satisfy the second objective is given in Table 2. 
 





polyphenol + LPS 
1 Complete α-MEM media 0 µg/ml 
2 Complete α-MEM media with LPS 0 µg/ml+100 µg/ml  
3 Complete α-MEM media with dried plum extract and LPS 1 µg/ml+100 µg/ml 
4 Complete α-MEM media with dried plum extract and LPS 10 µg/ml+100 µg/ml 
5 Complete α-MEM media with dried plum extract and LPS 100 µg/ml+100 µg/ml 
6 Complete α-MEM media with dried plum extract and LPS 1000 µg/ml+100 µg/ml 
Number of samples=4 
3.2 Cell Culture            
 MC3T3-E1 osteoblast cell-line from newborn mouse calvaria from ATCC (Manassas, 
VA) were grown in 75 cm2 flasks at 37 °C in humidified 5% CO2 atmosphere in α-MEM 
(Gibco, NY, USA) supplemented with 10% FBS (v/v) and 1% penicillin (v/v). 
Subcultures were carried out using a 0.25 % trypsin and 0.03% EDTA solution (Gibco, 
NY, USA). RAW-264 macrophage cell line from ATCC was another type of cell used in 





MC3T3-E1 cell line was not a good model for detecting pro-inflammatory molecules, 
RAW-264 cells were used to detect proinflamatory molecules such as COX-2 and nitric 
oxide. This type of cells can grow under 10% CO2 and at 37°C. The media used for this 
experiment was D-MEM with 1% penicillin/streptomycin from GIBCO Inc. (NY, USA) 
and 10% fetal bovine serum from GIBCO Inc.  Media was changed every 2 days.  
3.3 Ultrasound-assisted aqueous methanol extraction of polyphenolics: 
In this method, 80% aqueous methanol and ultrasound are used to extract 
polyphenolics from freeze-dried powdered plant material according to the methods of. 
Ultrasound-assisted extraction is rapid and efficient method for the extraction of 
polyphenolics. Low-frequency, high-energy, high-power ultrasound in the kHz range has 
the advantage of significantly reducing extraction time and enhancing extraction yield. 
Ten grams of ground freeze-dried dried plum was accurately weighed was mixed 
with 100 ml of 80% aqueous methanol in 500-ml Erlenmeyer flask and sonicate for 20 
min at room temperature with continual nitrogen gas purging and periodic shaking.  
Mixtures were filtered through Whatman number 2 filter paper using a vacuum suction a 
chilled buchner funnel. The filter cake was rinsed with 50 ml absolute methanol and 
residue was re-extracted with 100 ml of 80% aqueous methanol by repeating pervious 
steps. Filtrates were transferred to a 1000-ml round-bottom evaporating flask with 50 ml 
of 80% aqueous methanol. Methanol were evaporated in rotary evaporator under vacuum 
at 40°C until the volume of extract was reduced to 10 to 30 ml. The concentrate to a 100-
ml volume with deionized distilled water. Nitrogen gas were flushed in to the container to 






3.4 Separation of anthocyanin and non-anthocyanin fractions: 
Two C18 Sep-Pak cartridges were connected and precondition by sequentially 
passing 10 ml ethyl acetate, 10 ml absolute methanol, and 10 ml of 0.01 N aqueous HCl 
through the cartridges. Aqueous polyphenolic extract (sample) were filtered through a 
0.45-µm PVDF filter. A known volume filtered extract were loaded onto cartridges. 
Cartridges were washed with 6 ml of 0.01 N aqueous HCl to remove sugars, 
acids, and other water-soluble compounds. Cartridges were dried by allowing a current of 
nitrogen gas to pass through the connected Sep-Pak cartridges for 10 min. They were 
rinsed with 40 ml ethyl acetate to elute polyphenolic compounds other than anthocyanins 
and collect in a 100-ml round-bottom flask. The adsorbed anthocyanins from the 
cartridges with 6 ml acidic methanol and collected in a separate 50-ml round-bottom 
flask. 
The solvents were removed of the non-anthocyanin fraction and anthocyanin 
fraction using a rotary evaporator under reduced pressure. Ethyl acetate was evaporated 
at 20°C and methanol at 40°C or under nitrogen. Each fraction were dissolved in 5 ml 
deionized distilled water, flushed with nitrogen gas to prevent oxidation, and stored at  
-4°C until analysis. 
3.5 Objective 1 
3.5.1 Cell viability  
Cells were seeded into a 96 well plates with the density of 3,200 cells per well. 
After 24 hours incubation, cells were treated with different doses of dried plum 
polyphenol extract (0.0, 0.5, 1, 10, 100, 1000 µg/ml). Cell viability was assessed at 24 





Louis, MO) were added to each well and incubated for 3 hours at 37˚C under 10% CO2 
humidified atmosphere. Then the absorbance was measured at a wavelength of 570 nm 
and a reference wavelength of 650 nm. The absorbance were reported as nm. Similar 
experiment was carried out using RAW 264.7 cell line to observe the effect of 
lipopolysaccharide together with dried plum polyphenol extract on cell viability.  
 
3.5.2 Nodules formation and mineralization 
 
Cells were seeded in 6 well plates at density of 75,000 cells per well. Cells were 
treated with different doses of dried plum polyphenol extract (0.0, 0.5, 1, 10, 100, 1000 
µg/ml) for 15 days, cells the cultures were fixed in ice-cold 70% (v/v) ethanol for 1 hour 
and stained with alizarin red solution (40 mM, pH 4.2 Sigma Inc St Louis, MO) for 10 
min at room temperature. Mineralized nodules were counted by “Meta morph” software 
(Version 6.2.6) at a 10-fold magnification according to the method of Bielfy and 
colleagues  [26].  
3.5.3 Alkaline phosphatase activity 
 
After cells reached 80% confluency, they were treated with 6 different doses of 
dried plum polyphenol extract (see experimental design in Table 1 and Table 2). Media 
was changed every 3 days and at the same time supernatants were collected, aliquoted 
and kept at -20°C freezer. The experiment was continued for 15 days. ALP activity was 
measured utilizing an automated clinical chemistry analyzer (ACE, ALFA Wassermann 
,West Caldwell, NJ). In the reaction, the ALP catalyzed the hydrolysis of the colorless 





p-nitrophenol and phosphate. ALP was measured directly in the culture media without 
any chemical or mechanical cell lysing. Absorbance was measured at 340 to 692 nm. The 
values were reported as unit/liter. 
 
3.5.4 Nitric oxide 
After treatment, supernatants from MC3T3-E1 osteoblast-like cells and RAW 
microphages were collected for the measurement of nitrite, an indicator of nitric oxide 
(NO) production. The concentration of nitric oxide in the supernatant was measured by 
Griess assay. Briefly, 50µl aliquots of the cell supernatants were incubated with equal 
volumes of Griess assay reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% N-1-
napthylethylenediamine dihydrochloride, NED, in water). The absorbance was measured 
at wavelength between 520 to 550 nm by a mircoplate reader (ELx808 Biotek, MA). 
Nitrite concentration was derived from a standard curve generated using sodium nitrite 
(0.1M in water).  
3.6 Objective 2 
 
3.6.2 Protein level of Cox-2 in RAW 264.7 macrophages by western blot on  
 
Cells were seeded in 6 well plates at density of 357,800 cells per well, exposed to 
1 µg/ml LPS, then treated with different doses of dried plum polyphenol extract (0, 0.5, 
1, 10, 100, 1000 µg/ml) as described under experimental design . When cells reached 
80% confluency, they were washed with phosphate buffer saline (PBS) twice. Then 300 





mmol/L EDTA, 100 mmol/L DTT, protease inhibitor cocktail and 10% IGEPA was 
added to each plate. Plates were then incubated on ice while shaken on a rocking platform 
for 10 min at 150 rpm. Thereafter, cells were harvested and centrifuged at 15000×g for 3 
minutes at 4 °C.  Supernatants of cytosolic fractions were collected and stored at -80 °C.  
For measuring protein concentration, 200 µL mixtures of bicinchoinic acid and 
copper (49:1) were added into 5 µL cytosolic fraction using a 96 well-plate. Plates were 
then covered and incubated at room temperature for 20 minutes while being gently 
vibrated using a belly dancer (Stovall Life Science, Greensboro, NS). Absorbance was 
measured at wavelength of 570 nm.  
Equal amounts of protein (20 µg) was brought to volume of 12 µL by adding 
autoclave water, mixed with 12 µL loading buffer (0.125 mol/L Tris, 4 % sodium 
dodecyl sulfate (SDS) , 20 % glycerol, 10% 2-mercaptoethanol, 0.003% bromophenol 
blue pH 6.8)  and heated at 95-100 °C for 5 minutes. Protein was separated on 8% SDS-
polyacrylamide gel for 2 hrs (100v), and transferred to polyvinylidene diflouride (PVDF) 
membrane (Millipore, Bedford, MA) using a semi-dry blotting apparatus for one hour 
(15v).  Membrane was blocked with Tris-buffered saline (TBS, 8mmol/L Tris HCL, 
16mmol/L Tris-base, 150mmol/L NaCl) containing 5% skim milk for one hour. After 
washing in TBS, blots were incubated overnight with a 1:200 dilution of COX-2 (Santa 
Cruz Biotechnology, CA) antibody overnight. This was followed by 2-hour incubation 
with 1:2000 dilutions of goat polyclonal antibody (Santa Cruz Biotechnology, CA) in 
blocking buffer. The protein bands were developed using an Immuno-Star HRP substrate 
kit (Bio-Rad laboratories, Hercules, CA) and visualized using VersaDoc Imaging System 






3.7 Statistical Analysis  
All experiments were repeated four times and values were express as mean ± 
SEM of four measurements. Statistical analysis was preformed using analysis of variance 
(ANOVA) and least square means (LSM) were calculated using PROC-GLM by SAS 
(version 8.2, SAS Institute, Cary, NC). Difference among the means was considered 





CHAPTER IV                                                                                                 
RESULTS 
4.1 Effect of Prune Polyphenol Extract on Cell Viability 
The cell viability results for MC3T3-E1 and RAW264.7 macrophage cells are 
presented in [33,33]and [108], respectively. The resazurin system measures the metabolic 
activity of living cells. Solutions of resazurin are dark blue in color. Bioreduction of the 
dye by viable cells reduces the amount of its oxidized form (blue) and concomitantly 
increases the amount of its fluorescent intermediate (red), indicating the degree of 
cytotoxicity caused by the test agent. The plates were read by ELx 808 ultra microplate 
reader (BIO-TEK INC, Winooski, VT) and the background was subtracted in order to 
obtain the actual values.  
The results of resazurin assay demonstrated the viability of both types of cells was 
neither affected by treatment (Table 3) nor by LPS (Table 4, Figure 2)  
 
4.2 Effect of Prune Polyphenol Extract on Mineralized Nodule Formation 
Mineralized nodule formation in the presence or absence of 5 different 
concentration of polyphenol extract was determined on day 15 of MC3T3-E1 cell culture. 
Dense regions appeared on day 6 of culture which was confirmed as mineralization sites 
by alizarin red staining. The mineralized nodules became progressively more dense and 
enlarged by day 15 (Figure 5). In contrast, with the added polyphenol, mineralization was 
detected with the naked eye on day 15 of culture. The intensity of alizarin red staining on 






4.3 Alkaline Phosphatase Activity 
Alkaline phosphatase (ALP) activity was measured to study the effect of dried 
plum polyphenol extract on the osteoblastic differentiation in MC3T3-E1 cells. Alkaline 
phosphatase activity was determined for cells cultured with 6 different concentrations of 
dried plum extract on days 3, 6, 9, 12, and 15 of culture in. ALP activity increased 
gradually through day 6 (P value<0.0001) of culture and decreased by day 15 (P 
value<0.0001). Nonetheless, on days 6, 9, 12 and 15 of culture, the overall ALP activity 
was significantly more in all polyphenol-treated cells than in control cells (Tables 5-6).  
 
4.4 Nitric Oxide 
Nitric oxide leads to amplification of inflammation and tissue injury. This 
experiment was done to examine the anti-inflammatory and antioxidant properties of 
dried plum polyphenol extract, and the effects of polyphenol in LPS-stimulated (1µg/ml) 
RAW 264.7 cells on the pro-inflammatory and oxidative stress markers such as NO 
levels. LPS treatment of RAW 264.7 macrophages significantly (P value<0.0001) 
elevated NO generation by 16 times more than the LPS-untreated cells (Table 8). Dried 
plum polyphenol extract was found to suppress NO production in concentration-
dependent manner (Figure 5). As shown in Table 8 dried plum polyphenol extract dose-
dependently inhibited nitrite accumulation in LPS- activated RAW 264.7 cells. After 24 
hours of stimulation, LPS-treated cells increase NO production. Interestingly this LPS-
activated nitrite production was significantly (P<0.05) reduced by incubation with 






4.5 Inhibition of COX-2 Protein Expression 
We further investigated the effect of dried plum polyphenol extract on COX-2 
protein expression in RAW 264.7 cells using Western blotting. Our results showed that 
dried plum polyphenol extract significantly (P, value<0.0001) reduced the protein level 





CHAPTER V                                                                                        
DISCUSSION 
In this study, we have demonstrated that mineralized matrix formation is 
increased by dried plum polyphenol extract treatment in MC3T3-E1 cell line. At the 
cellular and molecular levels, polyphenol extract have been shown to inhibit osteoblast 
apoptosis [61],  impede cell cycle progression [111], increase nodule formation [109], and 
upregulated the expression of osteoblastic genes such as ALP [109]. Moreover, nitric 
oxide can activate COX pathway in endothelial, pancreas islet,  in vitro as well as in vivo 
as previously confirmed by several groups [121, 136]. Other researchers [143, 33] have 
shown that nitric oxide inhibits ALP activity via PGE2 and that PGE2, in turn, negatively 
modulates NO production. These results indicate that iNOS induced by cytokines 
mediates the production of NO. In the present study, we have demonstrated that 
inflammatory factor such as LPS induces the nitric oxide production and activates the 
COX pathway. Based on our result, the measurement of metabolic activity of living cells 
shows that polyphenol extract doesn’t have any toxic effect on either MC3T3-E1 or 
RAW264.7 macrophage cells as viability of these cells were not affected by the doses 
used in this study.  
While polyphenol extract had no effect on cell viability, it dose-dependently 
increased nodule formation. These results indicate that dried plum polyphenol extract 
enhance the activity of osteoblasts, especially the formation of hydroxyapatite crystals 
(Figure 5). 
The above findings were further supported by our observations that the activity of 





comparison with control cells. ALP, which hydrolyzes the ester bond of organic 
phosphate compounds under alkaline conditions, plays an important role in the 
calcification of bone [89].  Not only does the enzyme hydrolyze substances, it inhibits 
calcification, such as pyrophosphate and ATP, but it is also vital for producing the 
increased phosphate concentration required for hydroxyapatite crystallization. These 
findings are in agreement with those of Arjmandi et al. [21] and Deyhim et al. [40]. The 
study by Arjmandi and colleagues [21] suggest that dried plum diet was effective in 
preventing bone loss due to ovariectomy as indicated by higher bone densities, mineral 
contents, percent trabecular bone area, and tendency to reduce marrow space in 
comparison with OVX control rats. They [21], [40], concluded that dried plum elevated 
the rate of bone formation as suggested by a dose-dependent rise in serum IGF-I levels. 
Higher serum IGF-I concentrations are considered to be reflective of the elevated rate of 
bone formation.  
Deyhim et al. [39], studied the bone reversal properties of dried plum using 
osteopenic ovariectomized rat model. In that study [40], dried plum, as low as 5%, was 
effective in restoring femoral and tibial bone density. Dried plum also improved lumbar 
bone density.  The investigators similarly concluded that the improvement in bone 
density and biomechanical properties of long bones due to dried plum, in part, may be 
due to enhanced rate of bone formation.   
There is also evidence that polyphenolic compounds such as flavonoids [99], have 
anti-inflammatory effects that may exert beneficial effects on bone by suppressing the 
production of pro-inflammatory molecules.  In the present experiment, dried plum 





cells and was also able to reduce the protein level of COX-2 in LPS-stimulated 
macrophages. Therefore, our observations indicate that dried plum polyphenol extract has 
the capability to effectively suppress the production of pro-inflammatory molecules and 
thereby enhance bone formation. Dried plum polyphenols may act as powerful inhibitor 
of COX-2 activity and much of this effect may be through the inhibition of cytokines that 
mediate adhesion of circulating leukocytes to sites of injury. For example, Lin and 
colleagues [86,87] reported that flavonoids, a class of polyphenols, are powerful 
inhibitors of IL-1β, IL-6, TNF-α, and COX-2. Dried plum polyphenols may thus inhibit 
the inflammatory responses through these modes of action, suggesting that this class of 
molecules may be effective in conditions such as osteoporosis. However, much of this 
discussion is speculative and further research is needed to confirm the findings of this cell 
culture study. 
As to what components of dried plum polyphenol extract exert these bones 
protective effects remain to be answered. Dried plum polyphenol extract similar to whole 
fruit contain numerous compounds that make it difficult to discriminate the effect of one 
compound versus another. Dried plum polyphenol extract, in addition to being a good 
source of nutrients such as certain vitamins and minerals that can influence bone health, 
are a rich source of phenolic compounds that act as antioxidants. Hence, dried plum 
polyphenol-rich extract may exert positive effects on bone, in part, through their 
antioxidative capabilities. Dried plum, as a whole fruit, has been ranked highest  
 in antioxidant values [110] among the commonly eaten fruits and vegetables as assessed 
by ORAC, an in vitro analysis that measures the total antioxidant capacity of foods and 





Furthermore, the polyphenols in dried plum may protect bones similar to other 
phenolic compounds with estrogen-like activities such as isoflavones [140]. However, 
this is speculative and as to what extent polyphenols in dried plum have phytoestrogenic 





Table 3. Effect of different doses of polyphenol extract on cell viability of MC3T3-E1 at 24 
hours and 48 hours as assessed by resazurin assay  
Concentration 
µg/ml 
Cell Viability at 24 Hours Cell Viability at 48 Hours 
control 0.697±0.037005 0.79±0.091329 
0.5 0.775±0.078271 0.606±0.02669 
1 0.726±0.077272 0.605±0.059408 
10 0.758±0.078823 0.607±0.071253 
100 0.732±0.072542 0.597±0.037873 
1000 0.671±0.035595 0.575±0.040673 
Values are mean ± SE, n = 4. There were no significant differences among the treatments. 
 
 
Table 4. Effect of  different doses of LPS on all viability of RAW 264.7 at  24 hours as 
assessed by resazurin assay 
Concentration µg/ml Cell Viability at 24 Hours 
0 (control) 0.361±0.02375 































Figure 2. Cell viability of RAW 264.7 effect of different doses of dried plum polyphenol 
extract at 24 hours as assessed by resazurin assay. There were no significant differences 
among the treatments. 
 
 
Table 5. 15 days treatment of effect of  different doses of polyphenol extract on alkaline 
phosphatase activity of MC3T3-E1 cell. 
Polyphenol extract  
Concentration µg/ml 
Alkaline phosphatase activity, U/L 









Values are Mean ± SE, n = 4. Mean values that do not share the same letters are 





































Table 6. ALP activity Unit/L/Day 














Values are Mean ± SE, n = 4. Mean values that do not share the same letters are 







Figure 3. Effect of dried plum polyphenol extract on alkaline phosphatase activity at 



































Table 7. Represents number of nodule formation on day 15
th
 of cell culture. Cells were 
treated with 6 different concentrations of dried plum polyphenol extract.  












Values are mean ± SE, n = 4. Mean values that do not share the same letters are 














Figure 4. Effect of dried plum polyphenol extract on nodule formation of MC3T3-E1 cells at 
























Figure 5. (a) Specific histochemical staining for ALP. Detection of mineralized nodules by 
alizarin Red S staining in mouse osteoblast cultures grown for 15 days in normal growth 
medium supplemented with 10% FBS. The images show the differences between the cells 
cultured in αMEM supplemented with 10% FBS (a) cells were cultured in αMEM 
supplemented (b) 0.5 µg/ml (c) 1 µg/ml (d) 10 µg/ml. (e) 100 µg/ml, and (f) 1000 µg/ml dried 
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Table 8. Effect of dried plum polyphenol extract and LPS on NO production of RAW 246.7 
cells.  
 
LPS Con(1µg/ml) and Con of 
polyphenol (µg/ml) 













Values are mean ± SE, n = 4. Means that do not share the same letters are significantly 













































Figure 6. Effect of LPS and different doses of dried plum extract on NO production in 







































































Figure 7. Effect of LPS and various doses of died plum polyphenol extract of protein level of 
COX-2 as assessed by Western blot. 
(a) Represent active bands from the membrane and  
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Evidence for Bone Forming ability of Dried Plum Polyphenol Extract 
 
Our earlier findings indicate that dried plums are highly effective in preventing and 
reversing ovarian hormone deficiency-associated bone loss in a rat model of osteoporosis. 
Moreover, our short-term clinical trial showed that dried plum supplementation 
significantly increased indices of bone formation in postmenopausal women. The bone 
protective effect of dried plum, in part, may be due to its polyphenol content. The intent 
of the present study was to investigate the bone formation mechanisms of action of 
polyphenol extracted from dried plum using a cell culture system. We hypothesized that 
polyphenol extract from dried plum increases bone mineralization in MC3T3-E1 cell line. 
Also we hypothesized that polyphenol extract decrease pro-inflammatory molecules in 
macrophages. MC3T3-E1 cells were treated with various doses of polyphenol extract (0, 
0.5, 1, 10, 100, 1000 µg/ml). Media was collected every three days and analyzed for 
alkaline phosphatase activity. After 14 days, the formation of mineralized nodules was 
characterized by Alizarin red staining. Our findings indicate that dried plum polyphenol 
dose-dependently increases mineralization without affecting cell viability as shown by 
resazurin assay. Alkaline phosphatase activity was significantly increased at days six and 
nine. Among the doses tested, 100 µg/ml of polyphenol extract caused a significant 
elevation of alkaline phosphatase activity. For the second objective macrophages were 
stimulated with 100 ng/ml LPS and then they were treated with (1, 10, 100, and 1000 
µg/ml) polyphenol extract. Result showed that polyphenol extract decreased the 
production of pro-inflammatory molecules such as COX-2 and nitric oxide in 
macrophages. Overall, the finding of the present study suggests that dried plum 
polyphenol extract enhances bone formation and suppresses the production of 
inflammatory molecules known to be harmful to bone. 
 
